Total GAAP revenue reached $268 million for Q1 2026, a 10% increase year-over-year. DAYBUE net sales grew 20% year-over-year to $101 million. NUPLAZID net sales reached $167 million, a 5% increase compared to Q1 2025. Net income for the quarter was $4 million, or $0.02 per diluted share. Cash and investment position increased to $851 million as of March 31, 2026. Full-year 2026 financial guidance was reaffirmed across all key metrics.